Clinical TrialNov 12, 2026, 08:31 AM
Vivani Medical Reports Positive Phase 1 Trial Results for NPM-139 Implant
AI Summary
Vivani Medical announced positive top-line results from its Phase 1 SLIM-1 trial for NPM-139, a semaglutide implant for weight management. The trial showed a favorable safety and tolerability profile for NPM-139 compared to Wegovy, with comparable weight loss. The company plans to advance NPM-139 to a Phase 2 trial in 2027. In its third quarter financial results, Vivani reported a net loss of $7.3 million and a decrease in cash reserves.
Key Highlights
- Vivani Medical reports positive top-line results from Phase 1 SLIM-1 trial of NPM-139 semaglutide implant.
- NPM-139 showed no treatment-related adverse events; Wegovy group had 5/10 with GI issues.
- NPM-139 exhibited a slower semaglutide release profile (~16 days vs ~2.4 days for Wegovy).
- Comparable weight loss observed: 0.79% for NPM-139 vs 0.82% for Wegovy over 4 weeks.
- Company plans to advance NPM-139 to a Phase 2 dose-ranging trial in 2027.
- Vivani reported Q3 2026 net loss of $7.3 million, compared to $6.5 million in Q3 2025.
- Cash reserves decreased to $15.5 million as of September 30, 2026, from $20.8 million at June 30, 2026.
Price Impact
More from VANI